APC — Advanced Proteome Therapeutics Share Price
Last Trade - 00:00- CA$11.14m
- CA$8.39m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Jul | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Advanced Proteome Therapeutics Corporation is a biotechnology company. The Company is engaged in the development of anti-cancer therapeutics that exploit the properties of a natural human protein. The Company, through its subsidiary, Advanced Proteome Therapeutics Inc. (APTI), develops and commercializes a new technology platform that is intended for the chemical modification of protein therapeutics. The Foundation Trinity Technology is combining anti-cancer therapies in a single agent for targeted delivery to tumors. It is engaged in targeted therapy, immunotherapy and combination therapy. The Company's technology is applicable to the areas of therapeutics and diagnostics, protein drugs and personalized medicine, and is being applied to cancer therapeutics. It is focusing on enabling technology, designed to link antibodies to drugs or toxins, to produce pure and homogeneous antibody-drug conjugates (ADC).
Directors
- Last Annual
- July 31st, 2020
- Last Interim
- April 30th, 2021
- Incorporated
- January 1st, 1970
- Public Since
- April 4th, 1994
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 37,750,637
- Address
- 650 Albany St Ste 113, BOSTON, 02118-2518
- Web
- https://www.advancedproteome.com/
- Phone
- +1 6176380340
- Auditors
- Crowe MacKay LLP
Latest News for APC
Upcoming events for APC
Similar to APC
ACASTI PHARMA CL A ORD
TSX Venture Exchange
ALPHA COGNITION ORD
TSX Venture Exchange
ARCH BIOPARTNERS ORD
TSX Venture Exchange
BIOASIS TECHNOLOGIES ORD
TSX Venture Exchange
CEAPRO ORD
TSX Venture Exchange
FAQ
As of Today at 19:55 UTC, shares in Advanced Proteome Therapeutics are trading at CA$0.30. This share price information is delayed by 15 minutes.
Shares in Advanced Proteome Therapeutics last closed at CA$0.30 and the price had moved by +114.81% over the past 365 days. In terms of relative price strength the Advanced Proteome Therapeutics share price has outperformed the Toronto Stock Exchange 300 Composite Index by +74.07% over the past year.
There is no consensus recommendation for this security.
Advanced Proteome Therapeutics does not currently pay a dividend.
Advanced Proteome Therapeutics does not currently pay a dividend.
Advanced Proteome Therapeutics does not currently pay a dividend.
To buy shares in Advanced Proteome Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.30, shares in Advanced Proteome Therapeutics had a market capitalisation of CA$11.14m.
Here are the trading details for Advanced Proteome Therapeutics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: APC
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Advanced Proteome Therapeutics does not currently have a style classification.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanced Proteome Therapeutics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +52.85%.
As of the last closing price of CA$0.30, shares in Advanced Proteome Therapeutics were trading +15.53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Advanced Proteome Therapeutics.
Advanced Proteome Therapeutics' management team is headed by:
- Bill Dickie -
- Kenneth Phillippe -
- Alexander Krantz - COO
- John Garrett -
- Paul Woodward -
We do not have data on Advanced Proteome Therapeutics' shareholders